Warusevitane 2015.

Methods	Randomisation via a random numbers list generated by an independent statistician Double‐blind Analysis by ITT unclear
Participants	1 centre in UK 60 participants within 7 days of acute ischaemic or haemorrhagic stroke confirmed by CT scan of the brain who required nasogastric feeds for > 24 hours Mean age: 78 No significant differences between baseline characteristics
Interventions	Rx: 10 mg metoclopramide (10 mL) C: 10 mL normal saline Treatment duration: 21 days or until NGT no longer needed
Outcomes	Swallowing impairment using dysphagia outcome and severity scale
Notes	Exclusions: signs and symptoms of pneumonia after stroke onset, history of chronic neurodegenerative disease that could affect swallowing (e.g. Parkinson disease, motor neuron disease), oesophageal disorders, contraindications to metoclopramide.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation by numbers list generated by an independent statistician
Allocation concealment (selection bias)	Low risk	Allocation sequence concealed from participants
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blind trial
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind trial
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Researcher and medical team involved in participants' care blinded to treatment allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	All 60 participants analysed at end of trials (none excluded)
Selective reporting (reporting bias)	Low risk	All outcomes reported
Other bias	Low risk	None identified